Navigation Links
Eastern Europe's First Novalis Tx(TM) Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc(R) Technology

RIGA, Latvia, Oct. 14 /PRNewswire-FirstCall/ -- Doctors in Latvia have begun treatments using the region's first Novalis Tx(TM) radiosurgery platform from Varian Medical Systems (NYSE: VAR) and BrainLAB. Two prostate cancer patients have been treated using Varian's RapidArc® radiotherapy technology at the Riga Eastern Clinical University Hospital.

The Novalis Tx radiosurgery platform together with RapidArc technology enabled the clinicians to treat prostates with image-guided, intensity modulated radiotherapy (IMRT) in about half the time typically needed for conventional IMRT. "Our new radiosurgical instrument enabled us to spare surrounding healthy organs while precisely targeting the tumor with a high dose," said Dr. Sergey Popov, head of the hospital's radiotherapy department.

Dr. Popov said the Novalis Tx radiosurgery platform is the Baltic region's first machine for frameless intra-cranial stereotactic radiosurgery of brain lesions and he announced that cranial treatments would begin this month. Latvia's minister of health Prof. Baiba Rozentale is celebrating the arrival of the machine and the new treatment capability at a public ceremony today.

"The whole region has been waiting for this landmark as this machine represents the first ever stereotactic radiosurgery capability in any of the Baltic states of Latvia, Lithuania or Estonia," added Dr. Popov. "We chose the Novalis Tx radiosurgery platform because it gives us great clinical flexibility, enabling us to deliver RapidArc, IMRT, conformal treatments, and our first stereotactic radiosurgery techniques. In the past, patients have had to travel overseas for such treatments, mostly to Germany, but they will now receive state-of-the-art treatments here in Latvia."

The Novalis Tx radiosurgery platform features very high dose delivery rates, which contributes to shorter treatment times. It also offers dynamic fine beam shaping using the unique HD120(TM) high definition multi-leaf collimator (MLC) and non-invasive, precise patient positioning for rapid and more comfortable treatments. Specialized X-ray imaging systems are used to pinpoint the target and position the patient with millimeter accuracy, compensating for any motion that occurs during a treatment.

The Novalis Tx radiosurgery platform at Riga Eastern Clinical University Hospital will be used equally by radiation oncologists and neurosurgeons to deliver a wide range of advanced intra-cranial and extra-cranial treatments.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,100 people who are located at manufacturing sites in North America, China, and Europe and in its 79 sales and support offices around the world. For more information, visit

About BrainLAB

BrainLAB develops, manufactures and markets software-driven medical technology that enables procedures that are more precise, less invasive, and also less expensive than traditional treatments. Among the core products are image-guided systems that provide highly accurate real-time information used for navigation during surgical procedures. This utility has been further expanded to serve as a computer terminal for physicians to more effectively access and interpret diagnostic scans and other digital medical information for better informed decisions. BrainLAB solutions allow expansion from a single system to operating suites to digitally integrated hospitals covering all subspecialties from neurosurgery, orthopedics, ENT, CMF to spine & trauma and oncology. With 3300 systems installed in over 75 countries, BrainLAB is a market leader in image-guided technology. The privately held BrainLAB group, founded in 1989, is headquartered in Munich, Germany, and today employs 950 people in 16 offices across Europe, Asia, Australia, North and South America. For more information, visit

SOURCE Varian Medical Systems, Inc.

SOURCE Varian Medical Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
2. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
3. Positive Mosquito Count for West Nile Virus Lead DEP, Southeastern PA Counties to Ramp up Treatment Activities
4. DEP to Complete Aerial Mosquito Treatments to Stem West Nile Virus in Southeastern Counties
5. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
6. Widening Application Range to Boost MRI Markets in Eastern Europe, Says Frost & Sullivan
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
Breaking Medicine Technology:
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the perfect dish and pleasing the palates of attendees is of the utmost ... dish to a seasonal get-together, give these recipes a try this holiday season. ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and ... Pan African Centres of Excellence, and public R&D institutions, civil societies and other ... of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would ... OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE ... Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
Breaking Medicine News(10 mins):